Who are the applicable groups of WANSAVI?

Valcyte (Valcyte, valganciclovir hydrochloride) is an antiviral drug mainly used to treat and prevent infections caused by cytomegalovirus (CMV). The following are the main target groups of this drug.

Vansevir is most commonly used in organ transplant patients, especially to prevent and treatCMVinfection after transplantation. CMVInfection is a common complication in organ transplant patients and may cause serious complications such as rejection and organ failure. Vancevir can effectively prevent complications caused by CMV, especially for transplant patients with weak immune function (such as patients whose CMV negative recipients receive CMV positive donors). Preventive treatment is usually given several months after transplantation and may last for 3 to 12 months, depending on the patient's immune status and risk of infection.

For HIV infected patients, especially those with suppressed immune function, Vancevir is often used to treat complications such as retinitis and gastrointestinal infection caused by CMV. CMV Retinitis is one of the common causes of blindness in AIDS patients. The use of Vancevir in such patients can effectively control the disease and reduce the occurrence or recurrence of retinitis. This drug is usually used for patients with low CD4+ T cell counts, and the patient's immune function recovery needs to be closely monitored during treatment.

In addition to organ transplant and AIDS patients, Vancevir can also be used in other patients with suppressed immune systems, such as tumor patients receiving immunosuppressive treatment. Immunosuppressive treatment may lead to the occurrence ofCMVinfection. The application of Vancevir in these patients can effectively prevent the occurrence or recurrence of infection.

The applicable population of Vancevir mainly includes organ transplant patients, AIDS patients, and patients with suppressed immune systems, such as tumor patients receiving immunosuppressive treatment. Depending on the patient's immune function and infection risk, the use of Vancevir could play an important role in preventing and treatingCMVinfections.

xa0

Reference materials:

ValcyteDrug Instructions:https://www.drugs.com/pro/valcyte.html